Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 Views
administrator
07/02/23
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
-
Category
Show more
Facebook Comments
No comments found